• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

老年膀胱过度活动症患者中抗毒蕈碱药物与认知障碍的相关性研究。

Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.

机构信息

Department of Medicine, Division of Geriatric Medicine, University of Alberta, Edmonton, AB, Canada.

出版信息

Int J Clin Pract. 2010 Aug;64(9):1279-86. doi: 10.1111/j.1742-1241.2010.02449.x. Epub 2010 Jun 7.

DOI:10.1111/j.1742-1241.2010.02449.x
PMID:20529135
Abstract

Overactive bladder (OAB) will become an increasingly prevalent problem as the proportion of older people in the population increases over the next 20 years. In addition to the urological symptoms (urinary urgency, with or without urgency incontinence, usually with increased daytime frequency and nocturia), OAB is associated with other problems in older patients, especially an increased risk of falls and fractures. The bother caused by OAB needs not be an inevitable consequence of ageing, because the symptoms can usually be alleviated, even in frail older people. Pharmacological treatment for OAB involves the use of antimuscarinic agents, whose efficacy and safety profiles depend on their interactions with muscarinic receptors that are widely distributed throughout the body. Interactions between antimuscarinics and M(1) receptors in the central nervous system may have the potential to cause cognitive impairment in older people, depending on muscarinic receptor binding profiles, lipophilicity and the ability to cross the blood brain barrier. Concerns over the possibility of cognitive impairment have contributed to an under-utilisation of antimuscarinics in the geriatric population, despite the high prevalence and severity of OAB in older subjects. Antimuscarinic agents should be actively considered for elderly patients with OAB, but it is desirable to establish the cognitive risk for every type of antimuscarinic, using robust cognition assessment methods.

摘要

随着未来 20 年内人口中老年人比例的增加,膀胱过度活动症(OAB)将成为一个日益普遍的问题。除了泌尿系统症状(尿急,伴有或不伴有急迫性尿失禁,通常伴有白天尿频和夜尿增多)外,OAB 还与老年患者的其他问题相关,尤其是跌倒和骨折的风险增加。OAB 引起的困扰不一定是衰老的必然结果,因为这些症状通常可以缓解,即使是身体虚弱的老年人也是如此。OAB 的药物治疗涉及使用抗毒蕈碱药物,其疗效和安全性取决于它们与广泛分布于全身的毒蕈碱受体的相互作用。抗毒蕈碱药物与中枢神经系统中 M(1)受体的相互作用可能会导致老年人认知障碍,这取决于毒蕈碱受体结合谱、亲脂性和穿过血脑屏障的能力。对认知障碍可能性的担忧导致抗毒蕈碱药物在老年人群中的使用不足,尽管老年人中 OAB 的患病率和严重程度很高。对于患有 OAB 的老年患者,应积极考虑使用抗毒蕈碱药物,但最好使用可靠的认知评估方法,确定每种抗毒蕈碱药物的认知风险。

相似文献

1
Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.老年膀胱过度活动症患者中抗毒蕈碱药物与认知障碍的相关性研究。
Int J Clin Pract. 2010 Aug;64(9):1279-86. doi: 10.1111/j.1742-1241.2010.02449.x. Epub 2010 Jun 7.
2
Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients.用于治疗膀胱过度活动症的抗毒蕈碱药物及其对老年患者认知功能的潜在影响。
J Am Geriatr Soc. 2005 Dec;53(12):2195-201. doi: 10.1111/j.1532-5415.2005.00537.x.
3
Antimuscarinic agents: implications and concerns in the management of overactive bladder in the elderly.抗胆碱能药物:老年膀胱过度活动症管理中的影响与问题
Clin Ther. 2005 Jan;27(1):127-38; quiz 139-40. doi: 10.1016/j.clinthera.2005.01.006.
4
Muscarinic receptor antagonists for overactive bladder.用于治疗膀胱过度活动症的毒蕈碱受体拮抗剂。
BJU Int. 2007 Nov;100(5):987-1006. doi: 10.1111/j.1464-410X.2007.07205.x.
5
Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.膀胱过度活动症患者的心血管发病率、心率和抗毒蕈碱药物的使用。
BJU Int. 2010 Jul;106(2):268-74. doi: 10.1111/j.1464-410X.2009.09073.x. Epub 2009 Nov 17.
6
Understanding the elements of overactive bladder: questions raised by the EPIC study.了解膀胱过度活动症的要素:EPIC研究提出的问题
BJU Int. 2008 Jun;101(11):1381-7. doi: 10.1111/j.1464-410X.2008.07573.x. Epub 2008 Mar 10.
7
Overactive bladder in the elderly: a guide to pharmacological management.老年人膀胱过度活动症:药物治疗指南
Drugs Aging. 2005;22(12):1013-28. doi: 10.2165/00002512-200522120-00003.
8
Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).索利那新治疗膀胱过度活动症后的症状困扰及健康相关生活质量结局:卫喜康开放标签试验(VOLT)
Clin Ther. 2006 Nov;28(11):1935-46. doi: 10.1016/j.clinthera.2006.11.010.
9
Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.索利那新用于治疗伴有尿失禁的膀胱过度活动症:症状困扰及与健康相关的生活质量结果
Ann Pharmacother. 2007 Mar;41(3):391-8. doi: 10.1345/aph.1H581. Epub 2007 Mar 6.
10
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service.在英国国家医疗服务体系中,索利那新与非索罗定、奥昔布宁速释制剂、丙哌维林、托特罗定缓释制剂和托特罗定速释制剂治疗膀胱过度活动症患者的成本效益比较。
BJU Int. 2010 Aug;106(4):506-14. doi: 10.1111/j.1464-410X.2009.09160.x. Epub 2010 Feb 3.

引用本文的文献

1
Phytomedicines in Pharmacotherapy of LUTS/BPH - What Do Patients Think?植物药在LUTS/BPH药物治疗中的应用——患者怎么看?
Patient Prefer Adherence. 2024 Dec 9;18:2507-2518. doi: 10.2147/PPA.S484632. eCollection 2024.
2
Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.≥55岁成年人使用抗胆碱能药物治疗膀胱过度活动症与痴呆风险的关系:巢式病例对照研究
BMJ Med. 2024 Nov 12;3(1):e000799. doi: 10.1136/bmjmed-2023-000799. eCollection 2024.
3
A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder.
一项评估维贝格隆治疗韩国膀胱过度活动症患者疗效和安全性的随机、双盲、安慰剂对照桥接研究。
Int Neurourol J. 2023 Jun;27(2):106-115. doi: 10.5213/inj.2346022.011. Epub 2023 Jun 30.
4
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study.抗胆碱能药物治疗过度活跃膀胱与导致急诊科就诊的跌倒有关:ADRED 研究结果。
Eur J Clin Pharmacol. 2023 Sep;79(9):1185-1193. doi: 10.1007/s00228-023-03530-3. Epub 2023 Jun 29.
5
Discovery of PIPE-359, a Brain-Penetrant, Selective M Receptor Antagonist with Robust Efficacy in Murine MOG-EAE.PIPE-359的发现,一种具有脑渗透性的选择性M受体拮抗剂,在小鼠MOG-EAE模型中具有强大疗效。
ACS Med Chem Lett. 2020 Dec 24;12(1):155-161. doi: 10.1021/acsmedchemlett.0c00626. eCollection 2021 Jan 14.
6
Neurogenic Bladder: Epidemiology, Diagnosis, and Management.神经原性膀胱:流行病学、诊断与管理。
Semin Neurol. 2020 Oct;40(5):569-579. doi: 10.1055/s-0040-1713876. Epub 2020 Oct 16.
7
Alzheimer's disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs.阿尔茨海默病及相关痴呆风险:比较非选择性和 M3 选择性膀胱抗毒蕈碱药物使用者。
Pharmacoepidemiol Drug Saf. 2020 Dec;29(12):1650-1658. doi: 10.1002/pds.5098. Epub 2020 Aug 27.
8
[Treatment of benign prostatic hyperplasia in geriatric patients-use and limitations of existing guidelines].老年患者良性前列腺增生的治疗——现有指南的应用与局限性
Urologe A. 2019 Sep;58(9):1029-1038. doi: 10.1007/s00120-019-0988-0.
9
The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis.《多发性硬化症下尿路功能障碍的管理》。
Curr Neurol Neurosci Rep. 2018 Jun 28;18(8):54. doi: 10.1007/s11910-018-0857-z.
10
Influence of the Short-term Intake of High Doses of Solifenacin and Trospium on Cognitive Function and Health-Related Quality of Life in Older Women With Urinary Incontinence.短期高剂量服用索利那新和曲司氯铵对老年女性尿失禁患者认知功能及健康相关生活质量的影响
Int Neurourol J. 2018 Mar;22(1):41-50. doi: 10.5213/inj.1834996.498. Epub 2018 Mar 31.